// Biotech and Pharma Therapeutics
Japan’s National Cancer Center Selects Paradigm for Nationwide Clinical Trial Network
November 6, 2024 / Precision Medicine / Japan / Cancer Genomic Screening / Clinical Trial Network / Paradigm Health
Japan’s National Cancer Center, PREMIA, and Paradigm Health have launched the LC-SCRUM-CD, a nationwide trial network advancing precision medicine by leveraging genomic screening, efficient data management, and enhanced patient trial access to improve cancer treatment outcomes.
An RNAi renaissance is creating a new generation of startups
November 6, 2024 / RNA Unterference Startups / RNAi Drug Delivery / Alnylam Pharma / Innovation
A surge of new startups, backed by significant funding, is pushing RNA interference (RNAi) technology beyond liver-focused treatments to broader applications, aiming to address diseases involving organs like the brain, kidneys, and muscles.
Prioritize skills above infrastructure in UK meds manufacturing, expert says
November 6, 2024 / UK Medicine Manufacturing / Workforce Development / Life Sciences / Rachel Reeves Funding
UK experts welcome funding for medicine manufacturing infrastructure but emphasize prioritizing workforce skills development to strengthen the sector’s resilience and long-term growth.
4 Steps to Patient-Centric Incident Response in Healthcare
November 6, 2024 / Patient-centric Cybersecurity Healthcare / Patient Safety / Healthcare
Healthcare must adopt a patient-centric incident response to cyberattacks, prioritizing patient care over data alone. This involves a four-step plan focusing on patients, staff, families, and system recovery to mitigate patient impact.
Medtronic, Recor win CMS transitional payment coverage for renal denervation devices
November 5, 2024 / CMS Renal Denervation Coverage / Medtroonic Symplicaity Spryal / Hypertension Treatment
CMS granted Medtronic and Recor temporary payment support for their FDA-approved renal denervation devices, facilitating access to new hypertension treatments while gathering data for long-term reimbursement decisions.
// 4th Industrial Revolution
AdventHealth Manchester Opens First Telehealth Primary Care Clinic in Walmart
November 6, 2024 / AdventHealth Telehealth Clinic / Walmart / Corbin Healthcare Access / Chronic Disease Management / Virtual Primary Care Services / Telehealth
AdventHealth Manchester has opened its first telehealth primary care clinic in a Corbin Walmart, offering accessible, holistic care through virtual consultations, chronic disease management, and preventative services.
AI and Automation-Driven Efficiency: Driving Improvement Across the Healthcare Administration Ecosystem While Empowering Staff
November 6, 2024 / AI in Healthcare Administration / RPA Benefits / Healthcare AI
AI and automation improve healthcare administration by optimizing call centers and streamlining claims processing, freeing staff for complex tasks and enhancing service quality. Training strategies are key to maximizing these tools’ impact.
Why won’t this expert’s clients sign onto AI projects for more than 12 months at a time?
November 5, 2024 / Healthcare AI Adoption Challenges / Build vs. Buy / Healthcare AI
Healthcare CIOs hesitate to commit to AI contracts beyond 12 months due to rapid market shifts and unproven long-term vendor stability. This cautious approach emphasizes the need for flexible, patient-centric AI integration as the technology matures.
Reducing Clinical and Staff Burnout with AI Automation
November 5, 2024 / AI Automation / Healthcare / Clinician Burnout
AI-driven automation eases clinician burnout by reducing administrative workloads, optimizing scheduling, and improving documentation efficiency, allowing healthcare staff to focus more on patient care and reduce stress-related impacts.
Overcoming Barriers to Generative AI in Life Sciences R&D
November 4, 2024 / Generative AI / Drug Discovery / Life Sciences / AI Healthcare
Generative AI can transform life sciences R&D, accelerating drug discovery and data analysis. Key barriers include researcher trust, regulatory concerns, and integration challenges, requiring secure, user-friendly AI tools to foster collaboration and unlock new insights.
// Business & Markets
Research Grid secures $6.5M for AI automation engine for clinical trials
November 6, 2024 / AI Clinical Trial Automation / Research Grid Funding / Clinical Trial Data Management / Patient Engagement / TriEngine Platform
Research Grid, an AI-driven platform automating clinical trial workflows, raised $6.5M to enhance trial management and patient engagement tools. The funding supports R&D, market expansion, and workforce growth, targeting efficiency in clinical trials.
Teva’s generics and biosimilars fuel another booming quarter
November 6, 2024 / Teva Generics Growth / Growth Strategy / Innovations
Teva’s generics and biosimilars drove a strong Q3, with U.S. generics sales up 30%, boosting revenue and annual guidance. CEO Richard Francis’s balanced strategy focuses on generics alongside innovation, ensuring sustainable growth across Teva’s portfolio.
DarioHealth teams up with pharma company to boost user engagement
November 6, 2024 / DarioHealth / Pharma Partnership / DarioConnect / Digital Health Platform / Chronic Condition Management / Data Collection
DarioHealth partnered with a pharma company to use its DarioConnect platform for enhancing patient engagement and collecting data on psoriasis treatment outcomes, supporting insights into drug effectiveness and patient engagement trends.
Sense Neuro Diagnostics secures $2M contract for brain hemorrhage detection technology
November 6, 2024 / NeuroHawk Brain Hemorrhage Detection / Rapid TBI Detection Device
“Sense Neuro Diagnostics received a $2M DoD contract for clinical trials of NeuroHawk, a rapid, noninvasive brain hemorrhage detection device for TBI diagnosis in field conditions, enhancing triage decisions and improving treatment outcomes.
“
Half of US meds launched in 2023 ‘underperformed’
November 6, 2024 / US Drug Launch Performance / Trinity Life Sciences Report / Specialty Drug Overperformance / Pharma Product Launch Trends
In 2023, half of U.S. drug launches underperformed, marking an improvement from previous years as specialty drugs and first-launch companies drove higher success rates, per Trinity Life Sciences.
// Legal & Regulatory
A diabetes drug, twice rejected, stumbles again — but its developer persists
November 6, 2024 / Lexicon Pharmaceuticals Sotagliflosin / Type 1 Diabetes Adjunct Therapy / FDA Approval Challenges / Heart Failure Treatment / Diabetes and Kidney Disease Market
Despite setbacks with the FDA and advisory committee, Lexicon Pharmaceuticals continues efforts to secure U.S. approval for sotagliflozin in type 1 diabetes and chronic kidney disease, while positioning its other approved drug, Inpefa, amid competitive challenges.
BRIEF—Sun Pharma to appeal as injunction prevents US Leqselvi launch
November 6, 2024 / Sun Pharma / Leqselvi Launch Blocked / JAK Inhibitor / Alopecia Treatment / Incyte Patent Lawsuit
Sun Pharma’s U.S. launch of Leqselvi, a JAK inhibitor for severe alopecia areata, is blocked by a preliminary injunction over patent claims by Incyte. Sun plans to appeal the decision to proceed with its launch.
MHRA grants approval for bladder cancer drug erdafitinib
November 6, 2024 / MHRA Approval / Bladder Cancer Treatment / Johnson & Johnson
The MHRA has approved Johnson & Johnson’s erdafitinib (BALVERSA) for advanced bladder cancer patients with FGFR3 mutations, offering improved survival rates over chemotherapy and new hope for precision-targeted treatment options in the UK.
Six GOP lawmakers poised for power on health care as the Senate flips Republican
November 6, 2024 / GOP Healthcare Policy Senate / Senate Healthcare Agenda
With Republicans gaining Senate control, six GOP lawmakers will assume key roles influencing U.S. healthcare policy, including control of committees with authority over healthcare legislation, hearings, and investigations, impacting the sector’s direction.
Ionis Announces FDA Acceptance of New Drug Application for Donidalorsen for Prophylactic Treatment of HAE
November 4, 2024 / Ionis Donidalorsen HAE Treatment / FDA NDA Donidalorsen HAE / Clinical Trial Results / San Diego Biotech
The FDA accepted Ionis’s NDA for donidalorsen, an RNA-targeted treatment for hereditary angioedema (HAE), based on positive Phase 3 trial results. Approval is expected by August 2025, with potential to improve HAE prophylactic care.
// Research & Development
MacroGenics pauses work on vobra duo ADC pending mature survival data
November 6, 2024 / MacroGenetics / Prostate Cancer ADC Therapy / TAMARACK trial Prostate Cancer
MacroGenics is pausing development of its ADC, vobra duo, pending mature survival data from a Phase 2 prostate cancer trial. Future steps will depend on the final PFS data, safety profile, and competitive landscape.
Abbott touts long-term efficacy for dissolvable Esprit BTK stent
November 5, 2024 / Abbott Esprit BTK Stent Efficacy / Peripheral Artery Disease Treatment / LIFE-BTK Trial Results
Abbott’s Esprit BTK stent demonstrated strong two-year outcomes in treating severe peripheral artery disease (PAD), showing reduced reintervention rates and improved limb ischemia relief compared to angioplasty, highlighting its potential in managing advanced PAD cases.
Zymeworks doses first subject in Phase I trial of ZW191 for solid tumours
November 6, 2024 / Zymeworks ZW191 Phase 1 Trial / Antibody-drug Conjugate / Solid Tumor Therapy / Cancer Treatment
Zymeworks has initiated a Phase I trial of ZW191, an FRα-targeted antibody-drug conjugate, to treat advanced solid tumors, including endometrial, ovarian, and NSCLC, focusing on safety, tolerability, and anti-tumor efficacy.
Tango has last dance with PRMT5 inhibitor, pirouettes into embrace with 2 sibling molecules
November 6, 2024 / Tango Therapeutics / Brain Tumor Treatment / Cancer Combination Therapy
Tango Therapeutics has halted TNG908 for glioblastoma due to low brain exposure, shifting focus to TNG456, which shows better brain penetrance, and TNG462, effective in peripheral tumors and slated for combination studies in solid cancers.
Arcellx to present positive data on multiple myeloma treatments
November 6, 2024 / Arcellx Anito-cel Multiple Myeloma / Phase 2 Study Results / Cytokine Release Syndrome / Cell Therapy
Arcellx’s anito-cel therapy for relapsed/refractory multiple myeloma demonstrated promising efficacy with high response rates and improved safety, including minimal severe cytokine release syndrome and no neurotoxicity, to be presented at ASH 2024.
// Politics
Donald Trump returns to the presidency with big ambitions to shake up health care
November 6, 2024 / Donald Trump Healthcare Reform / RFK Jr. Health Policy Advisor / US Healthcare Cost Reduction / Public Health Agency Restructuring
President-elect Donald Trump plans to overhaul U.S. healthcare, with a focus on reducing costs and restructuring health agencies. He may enlist Robert F. Kennedy Jr. to lead initiatives on health, medicine, and food policy reform.
Trump triumphs but impact on healthcare industry remains unclear
November 6, 2024 / Trump Healthcare Policy / RKF Jr. / Public Health Control / Medicare Drug Pricing Reform / ACA Replacement Trump
Donald Trump’s re-election raises questions about potential healthcare changes, including RFK Jr.’s role in public health, possible Medicare drug pricing reforms, and a new Affordable Care Act replacement, though specifics remain largely unclear.
States slow to cover GLP-1s for weight loss
November 5, 2024 / Medicaid GLP-1 Coverage Obesity / Equity in Weight Loss Treatments / Medicaid / Obesity Medication Coverage Trends
Only 13 states currently cover GLP-1 drugs for weight loss through Medicaid due to budget constraints, raising equity concerns. Expanding coverage could benefit low-income populations with obesity but would strain state budgets.
Medicaid could be targeted for spending cuts under Trump
November 6, 2024 / Trump Medicaid Spending Cuts / Medicaid Private Insurer Impact / US Deficit Tax Cuts / Rural Hopitals Medicaid Reliance / Healthcare Budget
As Trump returns to office, Medicaid faces potential spending cuts to fund extended tax cuts, though private insurers and rural hospitals dependent on Medicaid could push back against these reductions.
Trump elected to the presidency again, as Republicans take the Senate
November 6, 2024 / Trump Healthcare Policy / Affordable Care Act Reform / Gender-affirming Care Regulations
Trump’s re-election, alongside a Republican Senate majority, signals potential shifts in U.S. healthcare policy, with likely impacts on the Affordable Care Act, abortion policy, and gender-affirming care regulations.